Testosterone Helps Rebuild Muscle in Some HIV-Infected Men
WebMD News Archive
Feb. 8, 2000 (Baltimore) -- Use of the male hormone testosterone helps
HIV-positive men who have low testosterone levels and loss of muscle mass --
called muscle wasting -- rebuild muscle and increase strength, according to a
study in the Feb. 9 issue of the Journal of the American Medical
"This is the first [study] to clearly show that testosterone replacement
in physiologic doses increases muscle mass and muscle strength, and that it is
useful in the treatment of muscle wasting associated with chronic disease,"
says lead author Shalender Bhasin, MD, professor of medicine at Charles R. Drew
University of Medicine and Science in Los Angeles, in an interview with WebMD.
Testosterone is one type of hormone called an anabolic steroid, which, among
other functions, helps the body build muscle mass.
Bhasin and colleagues studied 49 men who were HIV-positive and had both low
testosterone levels and muscle wasting for 16 weeks. The men were divided into
four groups: those who received a placebo; those who did resistance exercise
alone; those who received testosterone alone; and those who both received
testosterone and did resistance training (combination group).
Body weight and lean muscle mass increased by approximately 6 pounds in men
who either exercised or received testosterone. Those in the testosterone-only,
exercise-only, and combination groups realized significant increases in their
maximum muscle strength and thigh muscle size. The men receiving placebo did
not have any significant change in strength or muscle mass.
"Our study suggests that the use of testosterone in men who have low
testosterone levels and chronic muscle wasting will possibly increase muscle
mass and strength," Bhasin says. "The question is: Will this reduce
disability and improve function? These data do look promising, however, and the
increased mass and strength are seen without any tedious adverse
"This study shows a benefit from testosterone replacement in
HIV-infected men who have low testosterone levels," Adrian Dobbs, MD, tells
WebMD in an interview seeking objective comment on the study. "With the
initiation of early [anti-HIV] therapy, only about 5-10% of HIV-infected men
will experience low testosterone levels, so potential benefit in this group of
patients may be limited. However, in other chronic diseases where muscle
wasting is common, such as [emphysema,] this therapy might be quite effective.
In fact, we're recruiting patients with [emphysema] and lung cancer for such a
study right now, where we're using an inhaled anabolic steroid." Dobbs is
an associate professor of medicine at Johns Hopkins School of Medicine in